Grifols (NASDAQ:GRFS) Shares Up 5.1% – Here’s Why

Grifols, S.A. (NASDAQ:GRFS) shares rose 5.1% on Tuesday . The company traded as high as $8.02 and last traded at $8.01. Approximately 514,452 shares were traded during trading, a decline of 72% from the average daily volume of 1,834,552 shares. The stock had previously closed at $7.62.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Price Performance

The stock’s 50 day simple moving average is $8.37 and its 200-day simple moving average is $8.10. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The company has a market capitalization of $5.31 billion, a PE ratio of 7.96 and a beta of 0.43.

Hedge Funds Weigh In On Grifols

Several institutional investors have recently modified their holdings of the business. B. Riley Wealth Advisors Inc. acquired a new position in Grifols during the 2nd quarter worth $359,000. Sei Investments Co. increased its stake in shares of Grifols by 4.7% during the second quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock worth $13,931,000 after buying an additional 100,131 shares during the period. Melqart Asset Management UK Ltd acquired a new stake in Grifols in the third quarter valued at approximately $1,628,000. Hantz Financial Services Inc. purchased a new position in Grifols in the second quarter worth approximately $1,235,000. Finally, Verition Fund Management LLC purchased a new position in Grifols in the third quarter worth approximately $2,636,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.